Characteristics of patients, engraftment, GvHD occurrence, and GCV treatment, outcome, and immune response
| Patient . | Age, y . | Diagnosis . | Clinical status at time of BMT . | CD3+/tk+, ×105/kg . | GvHD . | Grade . | Response . | Follow-up, y (mo) after graft; remission . | Donor chimerism, % of mononuclear cells . | GMC-specific immune response . |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 51 | CML | CP | 6 | aGvHD (d 20) | II | CR (GCV + steroids) | 10.1 (121); CR | 80 | Yes |
| 7 | 61 | ALL-Ph+ | First CR1 | 6 | — | — | — | 10.1 (121); CR* | 80 | Not detectable |
| 8 | 53 | CML | CP | 6 | — | — | — | 9.8 y (119); CR | 100 | Yes |
| 9 | 52 | CML | CP | 6 | cGvHD (d 136) | — | CR (GCV) | 9.5 (115); CR | 100 | Yes |
| Patient . | Age, y . | Diagnosis . | Clinical status at time of BMT . | CD3+/tk+, ×105/kg . | GvHD . | Grade . | Response . | Follow-up, y (mo) after graft; remission . | Donor chimerism, % of mononuclear cells . | GMC-specific immune response . |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 51 | CML | CP | 6 | aGvHD (d 20) | II | CR (GCV + steroids) | 10.1 (121); CR | 80 | Yes |
| 7 | 61 | ALL-Ph+ | First CR1 | 6 | — | — | — | 10.1 (121); CR* | 80 | Not detectable |
| 8 | 53 | CML | CP | 6 | — | — | — | 9.8 y (119); CR | 100 | Yes |
| 9 | 52 | CML | CP | 6 | cGvHD (d 136) | — | CR (GCV) | 9.5 (115); CR | 100 | Yes |
CML indicates chronic myelogenous leukemia; CP, chronic phase; aGvHD, acute GvHD; CR, complete remission; ALL, acute lymphoblastic leukemia; cGvHD, chronic GvHD; —, not available.
Reappearance of a low level of Bcr/Abl transcripts 92 months after BMT.